

Kerry L Laplante

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7013255/publications.pdf>

Version: 2024-02-01

123
papers

4,459
citations

117625

34
h-index

118850

62
g-index

124
all docs

124
docs citations

124
times ranked

5681
citing authors

#	ARTICLE	IF	CITATIONS
1	Correction to: ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. American Journal of Gastroenterology, 2022, 117, 358-358.	0.4	1
2	Treatment, Clinical Outcomes, and Predictors of Mortality among a National Cohort of Admitted Patients with Acinetobacter baumannii Infection. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0197521.	3.2	14
3	Response to McFarland et al.. American Journal of Gastroenterology, 2022, Publish Ahead of Print, .	0.4	1
4	Impact of Clopidogrel on Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: a National Retrospective Cohort Study. Antimicrobial Agents and Chemotherapy, 2022, 66, e0211721.	3.2	8
5	Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. Annals of Medicine, 2022, 54, 1686-1700.	3.8	30
6	Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	25
7	Identification of a bacteria-produced benzisoxazole with antibiotic activity against multi-drug resistant Acinetobacter baumannii. Journal of Antibiotics, 2021, 74, 370-380.	2.0	8
8	ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. American Journal of Gastroenterology, 2021, 116, 1124-1147.	0.4	218
9	Poor clinical outcomes associated with suboptimal antibiotic treatment among older long-term care facility residents with urinary tract infection: a retrospective cohort study. BMC Geriatrics, 2021, 21, 436.	2.7	8
10	Antimicrobial Stewardship and the Infection Control Practitioner. Infectious Disease Clinics of North America, 2021, 35, 771-787.	5.1	4
11	A Review of Nonantibiotic Agents to Prevent Urinary Tract Infections in Older Women. Journal of the American Medical Directors Association, 2020, 21, 46-54.	2.5	13
12	Antibiograms Cannot Be Used Interchangeably Between Acute Care Medical Centers and Affiliated Nursing Homes. Journal of the American Medical Directors Association, 2020, 21, 72-77.	2.5	11
13	Trends in Collection of Microbiological Cultures Across Veterans Affairs Community Living Centers in the United States Over 8 Years. Journal of the American Medical Directors Association, 2020, 21, 115-120.	2.5	3
14	Synergistic antibacterial effects of analgesics and antibiotics against Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114967.	1.8	8
15	Evaluation of postflexible cystoscopy urinary tract infection rates. American Journal of Health-System Pharmacy, 2020, 77, 1852-1858.	1.0	10
16	Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and Î²-lactam antibiotics to maximize effectiveness and minimize toxicity. American Journal of Health-System Pharmacy, 2020, 77, 1104-1112.	1.0	51
17	Long-Term Care Facilities and the Coronavirus Epidemic: Practical Guidelines for a Population at Highest Risk. Journal of the American Medical Directors Association, 2020, 21, 569-571.	2.5	71
18	Frequency and Predictors of Suboptimal Prescribing Among a Cohort of Older Male Residents with Urinary Tract Infections. Clinical Infectious Diseases, 2020, 73, e2763-e2772.	5.8	4

#	ARTICLE	IF	CITATIONS
19	The authors reply:. Critical Care Medicine, 2020, 48, e1371-e1372.	0.9	0
20	Facilitators and Barriers to Antibiotic Stewardship: A Qualitative Study of Pharmacists' Perspectives. Hospital Pharmacy, 2019, 54, 250-258.	1.0	17
21	National trends in the treatment of urinary tract infections among Veterans Affairs Community Living Center residents. Infection Control and Hospital Epidemiology, 2019, 40, 1087-1093.	1.8	9
22	Weak biofilm formation among carbapenem-resistant Klebsiella pneumoniae. Diagnostic Microbiology and Infectious Disease, 2019, 95, 114877.	1.8	15
23	Biofilm prevention concentrations (BPC) of minocycline compared to polymyxin B, meropenem, and amikacin against Acinetobacter baumannii. Diagnostic Microbiology and Infectious Disease, 2019, 94, 223-226.	1.8	12
24	Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible Staphylococcus aureus Bloodstream Infection. Open Forum Infectious Diseases, 2019, 6, ofz270.	0.9	28
25	Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings. American Journal of Health-System Pharmacy, 2019, 76, 581-590.	1.0	22
26	Heterogeneity in the treatment of bloodstream infections identified from antibiotic exposure mapping. Pharmacoepidemiology and Drug Safety, 2019, 28, 707-715.	1.9	6
27	Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	112
28	Reply to Koehler et al. Clinical Infectious Diseases, 2019, 69, 901-902.	5.8	1
29	Reply to Kalil et al., "Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?" Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	2
30	What Is the Role for Metronidazole in the Treatment of Clostridium difficile Infection? Results From a National Cohort Study of Veterans With Initial Mild Disease. Clinical Infectious Diseases, 2019, 69, 1288-1295.	5.8	19
31	Re: Disparities Between Parental Expectations and Pediatric Antibiotic Prescribing. Pediatrics, 2018, 141, .	2.1	1
32	A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. Clinical Infectious Diseases, 2018, 67, 303-309.	5.8	150
33	Nephrotoxicity With Vancomycin in the Pediatric Population. Pediatric Infectious Disease Journal, 2018, 37, 654-661.	2.0	48
34	Antibiotic resistance rates for Pseudomonas aeruginosa clinical respiratory and bloodstream isolates among the Veterans Affairs Healthcare System from 2009 to 2013. Diagnostic Microbiology and Infectious Disease, 2018, 90, 311-315.	1.8	12
35	Clinical and Genetic Risk Factors for Biofilm-Forming Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	26
36	A pharmacist-driven academic detailing program to increase adult pneumococcal vaccination. Journal of the American Pharmacists Association: JAPhA, 2018, 58, 303-310.	1.5	16

#	ARTICLE	IF	CITATIONS
37	Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. <i>Critical Care Medicine</i> , 2018, 46, 12-20.	0.9	183
38	Association of Higher Daptomycin Dose (7Âmg/kg or Greater) with Improved Survival in Patients with Methicillinâ€Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Pharmacotherapy</i> , 2018, 38, 189-196.	2.6	27
39	1829. A Systems Approach to Nursing Home Antimicrobial Stewardship. <i>Open Forum Infectious Diseases</i> , 2018, 5, S520-S520.	0.9	0
40	1238. A National Comparison of Antibigrams Between Veterans Affairs Long-Term Care Facilities and Affiliated Hospitals. <i>Open Forum Infectious Diseases</i> , 2018, 5, S376-S377.	0.9	1
41	699. Relationship Between <i>Klebsiella pneumoniae</i> Antimicrobial Resistance and Biofilm Formation. <i>Open Forum Infectious Diseases</i> , 2018, 5, S252-S252.	0.9	0
42	Improved survival with continuation of statins in bacteremic patients. <i>SAGE Open Medicine</i> , 2018, 6, 205031211880170.	1.8	1
43	470. Concomitant Antibiotic Use and Death Among a National Cohort of Veterans With <i>Clostridium difficile</i> Infection (CDI). <i>Open Forum Infectious Diseases</i> , 2018, 5, S175-S176.	0.9	2
44	Predictors of Mortality Among a National Cohort of Veterans With Recurrent <i>Clostridium difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy175.	0.9	19
45	Colistin for the treatment of multidrug-resistant infections. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1174-1175.	9.1	11
46	Optimal duration for continuation of statin therapy in bacteremic patients. <i>Therapeutic Advances in Infectious Disease</i> , 2018, 5, 83-90.	1.8	1
47	Best Care for Patients Achieved Through Multidisciplinary Stewardship. <i>Clinical Infectious Diseases</i> , 2018, 67, 1637-1637.	5.8	11
48	Antimicrobial Stewardship in Long-Term Care Facilities: Approaches to Creating an Antibiogram when Few Bacterial Isolates Are Cultured Annually. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 744-747.	2.5	10
49	Overview of Antimicrobial Stewardship Activities in Rhode Island. <i>Rhode Island Medical Journal</i> (2013), 2018, 101, 22-25.	0.2	0
50	Communicating with Facility Leadership; Metrics for Successful Antimicrobial Stewardship Programs (Asp) in Acute Care and Long-Term Care Facilities. <i>Rhode Island Medical Journal</i> (2013), 2018, 101, 45-49.	0.2	1
51	Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study. <i>Hospital Practice</i> (1995), 2017, 45, 1-8.	1.0	14
52	Evidence To Support Continuation of Statin Therapy in Patients with <i>Staphylococcus aureus</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	19
53	Antimicrobial Resistance of <i>Escherichia coli</i> Urinary Isolates in the Veterans Affairs Health Care System. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	37
54	Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with <i>Streptococcus pneumoniae</i> infections. <i>Vaccine</i> , 2017, 35, 1692-1697.	3.8	20

#	ARTICLE	IF	CITATIONS
55	Comparison of linezolid and vancomycin lock solutions with and without heparin against biofilm-producing bacteria. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, e193-e201.	1.0	7
56	Inappropriate prescribing in outpatient healthcare: an evaluation of respiratory infection visits among veterans in teaching versus non-teaching primary care clinics. <i>Antimicrobial Resistance and Infection Control</i> , 2017, 6, 33.	4.1	11
57	Cranberry Capsules for Bacteriuria Plus Pyuria in Nursing Home Residents. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1078.	7.4	1
58	Predictors of Mortality Among U.S. Veterans With <i>Streptococcus Pneumoniae</i> Infections. <i>American Journal of Preventive Medicine</i> , 2017, 52, 769-777.	3.0	2
59	Assessments of Opportunities to Improve Antibiotic Prescribing in an Emergency Department: A Period Prevalence Survey. <i>Infectious Diseases and Therapy</i> , 2017, 6, 497-505.	4.0	37
60	Antibiotic Prescribing Pathway for Urinary Tract Infections: A "Low-Hanging Fruit" Antibiotic Stewardship Target in Nursing Homes. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2744-2745.	2.6	3
61	Are non-allergic drug reactions commonly documented as medication "allergies"? A national cohort of Veterans' admissions from 2000 to 2014. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 472-476.	1.9	14
62	The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2017, 64, 15-23.	5.8	365
63	Predictors of 30-day All-cause Mortality in Veterans with First Recurrence of <i>Clostridium difficile</i> Infection (CDI). <i>Open Forum Infectious Diseases</i> , 2017, 4, S399-S400.	0.9	0
64	Impact of Vancomycin-Associated Acute Kidney Injury on Patient Outcomes in MRSA Bacteremia. <i>Open Forum Infectious Diseases</i> , 2017, 4, S344-S344.	0.9	1
65	Risk Stacking of Pneumococcal Vaccination Indications Increases Mortality in Unvaccinated Adults With <i>Streptococcus pneumoniae</i> Infections. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
66	Antimicrobial Stewardship for the Infection Control Practitioner. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 771-784.	5.1	7
67	Antimicrobial Stewardship in Rhode Island Long-Term Care Facilities: Current Standings and Future Opportunities. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 979-982.	1.8	9
68	Daptomycin-induced eosinophilic pneumonia - a systematic review. <i>Antimicrobial Resistance and Infection Control</i> , 2016, 5, 55.	4.1	46
69	Vancomycin plus Piperacillin/Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	6
70	Verbal Communication With Providers Improves Acceptance of Antimicrobial Stewardship Interventions. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 740-742.	1.8	17
71	Antimicrobial Stewardship in Long-Term Care Facilities: A Call to Action. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 183.e1-183.e16.	2.5	64
72	Comparison of telavancin and vancomycin lock solutions in eradication of biofilm-producing staphylococci and enterococci from central venous catheters. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 315-321.	1.0	5

#	ARTICLE	IF	CITATIONS
73	Ampicillin in Combination with Ceftazidime, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum <i>Enterococcus faecalis</i> Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3178-3182.	3.2	21
74	Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Program at a Veterans Affairs Medical Center: A Six-Point Assessment. <i>PLoS ONE</i> , 2016, 11, e0150795.	2.5	33
75	Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients. <i>Pharmacotherapy</i> , 2015, 35, 869-875.	2.6	22
76	Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv050.	0.9	315
77	Cranberry (<i>Vaccinium macrocarpon</i>) oligosaccharides decrease biofilm formation by uropathogenic <i>Escherichia coli</i> . <i>Journal of Functional Foods</i> , 2015, 17, 235-242.	3.4	58
78	Overconsumption of antibiotics. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 377-378.	9.1	4
79	Clinical Implications of Vancomycin Heteroresistant and Intermediately Susceptible <i>Staphylococcus aureus</i> . <i>Pharmacotherapy</i> , 2015, 35, 424-432.	2.6	49
80	Ethanol and Isopropyl Alcohol Exposure Increases Biofilm Formation in <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> . <i>Infectious Diseases and Therapy</i> , 2015, 4, 219-226.	4.0	39
81	Observed Antagonistic Effect of Linezolid on Daptomycin or Vancomycin Activity against Biofilm-Forming Methicillin-Resistant <i>Staphylococcus aureus</i> in an <i>In Vitro</i> Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7790-7794.	3.2	15
82	Impact of an Antimicrobial Stewardship Program (ASP) on antimicrobial use and clinical outcomes at a Veterans Affairs (VA) Teaching Hospital. <i>Open Forum Infectious Diseases</i> , 2014, 1, S98-S98.	0.9	0
83	Virulence profile. <i>Virulence</i> , 2014, 5, 691-694.	4.4	0
84	Comparative Effectiveness of Linezolid and Vancomycin Among a National Veterans Affairs Cohort with Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia. <i>Pharmacotherapy</i> , 2014, 34, 473-480.	2.6	18
85	Predictors of Clinical Success Among a National Veterans Affairs Cohort With Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia. <i>Clinical Therapeutics</i> , 2014, 36, 552-559.	2.5	2
86	Risk of hepatotoxicity associated with fluoroquinolones: A national case-control safety study. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 37-43.	1.0	52
87	Activity of Daptomycin or Linezolid in Combination with Rifampin or Gentamicin against Biofilm-Forming <i>Enterococcus faecalis</i> or <i>E. faecium</i> in an <i>In Vitro</i> Pharmacodynamic Model Using Simulated Endocardial Vegetations and an <i>In Vivo</i> Survival Assay Using <i>Galleria mellonella</i> Larvae. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4612-4620.	3.2	71
88	Comparison of ML8-X10 (a prototype oil-in-water micro-emulsion based on a novel free fatty acid), taurolidine/citrate/heparin and vancomycin/heparin antimicrobial lock solutions in the eradication of biofilm-producing staphylococci from central venous catheters. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3263-3267.	3.0	19
89	Antibacterial Activities of Amphiphilic Cyclic Cell-Penetrating Peptides against Multidrug-Resistant Pathogens. <i>Molecular Pharmaceutics</i> , 2014, 11, 3528-3536.	4.6	55
90	Activities of Tobramycin and Polymyxin E against <i>Pseudomonas aeruginosa</i> Biofilm-Coated Medical Grade Endotracheal Tubes. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1723-1729.	3.2	16

#	ARTICLE	IF	CITATIONS
91	Antimicrobial stewardship program prompts increased and earlier infectious diseases consultation. <i>Antimicrobial Resistance and Infection Control</i> , 2014, 3, 12.	4.1	16
92	Epidemiology of Pneumococcal Disease in a National Cohort of Older Adults. <i>Infectious Diseases and Therapy</i> , 2014, 3, 19-33.	4.0	35
93	Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4252-4259.	3.2	68
94	Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1405-1409.	1.0	8
95	<i>In Vitro</i> Coagulation Effects of Ophthalmic Doses of Bevacizumab. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 219-221.	1.4	2
96	Inhibition of Bacterial Growth and Biofilm Production by Constituents from <i>Hypericum</i> spp.. <i>Phytotherapy Research</i> , 2012, 26, 1012-1016.	5.8	28
97	Effects of Cranberry Extracts on Growth and Biofilm Production of <i>Escherichia coli</i> and <i>Staphylococcus</i> species. <i>Phytotherapy Research</i> , 2012, 26, 1371-1374.	5.8	62
98	Changing epidemiology of methicillin-resistant <i>Staphylococcus aureus</i> in the Veterans Affairs Healthcare System, 2002–2009. <i>Infection</i> , 2012, 40, 291-297.	4.7	22
99	Low Adherence to Outpatient Preoperative Methicillin-Resistant <i>Staphylococcus aureus</i> Decolonization Therapy. <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 930-932.	1.8	26
100	Risk factors associated with mupirocin resistance in methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Hospital Infection</i> , 2010, 76, 206-210.	2.9	64
101	Diversity-oriented synthesis of cyclic acyldepsipeptides leads to the discovery of a potent antibacterial agent. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 7193-7202.	3.0	61
102	Comparative Effectiveness of Linezolid and Vancomycin among a National Cohort of Patients Infected with Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4394-4400.	3.2	13
103	In vitro activity of tigecycline in combination with gentamicin against biofilm-forming <i>Staphylococcus aureus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 1-6.	1.8	19
104	In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing <i>Staphylococcus aureus</i> , <i>S. epidermidis</i> , and <i>Enterococcus faecalis</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3166-3169.	3.2	73
105	Activities of Daptomycin and Vancomycin Alone and in Combination with Rifampin and Gentamicin against Biofilm-Forming Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates in an Experimental Model of Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3880-3886.	3.2	101
106	Evaluating Aztreonam and Ceftazidime Pharmacodynamics with <i>Escherichia coli</i> in Combination with Daptomycin, Linezolid, or Vancomycin in an In Vitro Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4549-4555.	3.2	23
107	Agents for the Decolonization of Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Pharmacotherapy</i> , 2009, 29, 263-280.	2.6	82
108	Structure–activity studies of echinomycin antibiotics against drug-resistant and biofilm-forming <i>Staphylococcus aureus</i> and <i>Enterococcus faecalis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1504-1507.	2.2	25

#	ARTICLE	IF	CITATIONS
109	Prevalence of and Risk Factors for Dysglycemia in Patients Receiving Gatifloxacin and Levofloxacin in an Outpatient Setting. <i>Pharmacotherapy</i> , 2008, 28, 82-89.	2.6	25
110	Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> with Inducible Clindamycin Resistance in Murine Thigh Infection and In Vitro Pharmacodynamic Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2156-2162.	3.2	91
111	Cephalosporin use in treatment of patients with penicillin allergies. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2008, 48, 530-540.	1.5	92
112	Fluoroquinolone Resistance in <i>Streptococcus pneumoniae</i> : Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1315-1320.	3.2	29
113	Telavancin: A novel lipoglycopeptide antimicrobial agent. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 2335-2348.	1.0	39
114	In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2239-2246.	0.7	79
115	In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant <i>Staphylococcus aureus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 413-418.	1.8	58
116	Antimicrobial Susceptibility and Staphylococcal Chromosomal CassettemecType in Community- and Hospital-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Pharmacotherapy</i> , 2007, 27, 3-10.	2.6	29
117	New bisanthraquinone antibiotics and semi-synthetic derivatives with potent activity against clinical <i>Staphylococcus aureus</i> and <i>Enterococcus faecium</i> isolates. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 8446-8454.	3.0	50
118	Oritavancin – an investigational glycopeptide antibiotic. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 417-429.	4.1	21
119	Impact of <i>Enterococcus faecalis</i> on the Bactericidal Activities of Arbekacin, Daptomycin, Linezolid, and Tigecycline against Methicillin-Resistant <i>Staphylococcus aureus</i> in a Mixed-Pathogen Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1298-1303.	3.2	18
120	Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> : A Review. <i>Pharmacotherapy</i> , 2005, 25, 74-85.	2.6	104
121	Impact of High-Inoculum <i>Staphylococcus aureus</i> on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4665-4672.	3.2	270
122	Daptomycin – a novel antibiotic against Gram-positive pathogens. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2321-2331.	1.8	65
123	Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 50, 125-130.	1.8	36